TABLE 4.
No. With Episodes | PAR, % | No. of Episodes Attributable to SHS | Cost per Episode, 2003 $ | Total Cost, Millions of 2003 $ | Total Cost, Millions of 2008 $ | |
Aged 0–17 ya | ||||||
Low birthweight | 4 413 | 18.0 | 794 | 41 790 | 33.2 | 40.3 |
Acute lower-respiratory illnesses | 31 953 | 25.0 | 7 988 | 848 | 6.8 | 8.2 |
Otitis media and middle-ear effusion | 235 333 | 14.0 | 32 947 | 521 | 17.2 | 20.9 |
Asthma, wheeze illness | 50 135 | 35.0 | 17 547 | 1 052 | 18.5 | 22.4 |
Aged 18–64 yb | ||||||
Lung cancer | 3 466 | 4.9 | 170 | 23 200 | 3.9 | 4.8 |
Coronary heart disease | 73 914 | 6.9 | 5 100 | 9 650 | 49.2 | 59.7 |
Aged ≥ 65 yb | ||||||
Lung cancer | 4 450 | 4.9 | 218 | 58 303 | 12.7 | 15.4 |
Coronary heart disease | 28 033 | 6.9 | 1 934 | 24 252 | 46.9 | 56.9 |
Grand total | 228.7 |
Note. PAR = population attributable risk.
PAR for asthma and wheeze illness were calculated from the 2006 surgeon general's report1 and prevalence data from the Minnesota Department of Health32; PAR for low birthweight, acute lower respiratory illnesses, otitis media, and middle-ear effusion were calculated from Zollinger et al.9
PAR for lung cancer and coronary heart disease calculated from Zollinger et al.9 and Woodward and Laugesen.29 The California Environmental Protection Agency 2005 report Proposed Identification of Environmental Tobacco Smoke as a Toxic Air Contaminant10 includes a review of scientific studies in the United States and finds PARs in the range of 2.2% to 5.6% for lung cancer and 2.5% to 8.0% for coronary heart disease.